Trial Profile
Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2020
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.
- 26 Apr 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 26 Apr 2019 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2019.